13,14-dihydro-15(R,S)-hydroxy-16,16-difluoro Prostaglandin E1-d4

Request For Quotation
13,14-dihydro-15(R,S)-hydroxy-16,16-difluoro Prostaglandin E1-d4 Suppliers list
Company Name: ChemeGen  
Tel: 18818260767
Email: 2625930290@qq.com
13,14-dihydro-15(R,S)-hydroxy-16,16-difluoro Prostaglandin E1-d4 Basic information
Product Name:13,14-dihydro-15(R,S)-hydroxy-16,16-difluoro Prostaglandin E1-d4
Synonyms:13,14-dihydro-15(R,S)-hydroxy-16,16-difluoro Prostaglandin E1-d4
CAS:
MF:C20H30D4F2O5
MW:396.502413512
EINECS:
Product Categories:
Mol File:Mol File
13,14-dihydro-15(R,S)-hydroxy-16,16-difluoro Prostaglandin E1-d4 Structure
13,14-dihydro-15(R,S)-hydroxy-16,16-difluoro Prostaglandin E1-d4 Chemical Properties
solubility DMF: 10 mg/ml
DMSO: 5 mg/ml
Ethanol: 10 mg/ml
Ethanol: PBS(pH 7.2) (1:1): 0.5 mg/ml
Safety Information
MSDS Information
13,14-dihydro-15(R,S)-hydroxy-16,16-difluoro Prostaglandin E1-d4 Usage And Synthesis
DescriptionPGE1 is produced by the metabolism of dihomo-γ-linolenic acid (DGLA) by the cyclooxygenase pathway. PGE1 inhibits platelet aggregation (IC50 = 40 nM) and increases vasodilation.1,213,14-dihydro-16,16-difluoro PGE1 is a biologically active metabolite of PGE1, inhibiting platelet aggregation with comparable potency to the parent compound.3,2 The addition of two electron-withdrawing fluorine atoms, which should stabilize the molecule against hydrolytic cleavage, may be expected to delay degradation in vivo.4 13,14-dihydro-15(R,S)-hydroxy-16,16-difluoro PGE1-3,3’,4,4’-d4) contains four deuterium atoms at the 3, 3’, 4, and 4’ positions. It is intended for use as an internal standard for the quantification of 13,14-dihydro-15(R,S)-hydroxy-16,16-difluoro Prostaglandin E1 by GC- or LC-mass spectrometry (MS).WARNING This product is not for human or veterinary use.
References[1] I. JÄRVING. ANTIAGGREGATING POTENCY OF E-TYPE PROSTAGLANDINS IN HUMAN AND RABBIT PLATELETS[J]. Proceedings of the Estonian Academy of Sciences. Chemistry, 1991, 32 1. DOI: 10.3176/chem.1991.3.09
[2] WESTWICK J. The effect of pulmonary metabolites of prostaglandins E1, E2 and F2alpha on ADP-induced aggregation of human and rabbit platelets [proceedings].[J]. British Journal of Pharmacology, 1976, 58 2: 297P-298P.
[3] B A PESKAR. On the metabolism of prostaglandin E1 administered intravenously to human volunteers.[J]. Journal of Physiology and Pharmacology, 1991, 42 3: 327-331.
[4] Y HATANO. Vascular relaxing activity and stability studies of 10,10-difluoro-13,14-dehydroprostacyclin.[J]. Proceedings of the National Academy of Sciences of the United States of America, 1980, 77 11: 6846-6850. DOI: 10.1073/pnas.77.11.6846
13,14-dihydro-15(R,S)-hydroxy-16,16-difluoro Prostaglandin E1-d4 Preparation Products And Raw materials
Tag:13,14-dihydro-15(R,S)-hydroxy-16,16-difluoro Prostaglandin E1-d4 Related Product Information
13,14-Dihydro-15-keto prostaglandin E1-d4 13,14-Dihydro prostaglandin E1-d4 13,14-Dihydro-15(R)-prostaglandin E1 15-Hydroxy Lubiprostone HNLDBJMVKYEERT-FSNPWBFUSA-N